Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Safety, pharmacokinetics and antiviral activity of AT-527, a novel purine nucleotide prodrug, in HCV-infected subjects with and without cirrhosis.

Berliba E, Bogus M, Vanhoutte F, Berghmans PJ, Good SS, Moussa A, Pietropaolo K, Murphy RL, Zhou XJ, Sommadossi JP.

Antimicrob Agents Chemother. 2019 Sep 30. pii: AAC.01201-19. doi: 10.1128/AAC.01201-19. [Epub ahead of print]

2.

Pharmacokinetics of IDX184, a liver-targeted oral prodrug of 2'-methylguanosine-5'-monophosphate, in the monkey and formulation optimization for human exposure.

Pan-Zhou XR, Mayes BA, Rashidzadeh H, Gasparac R, Smith S, Bhadresa S, Gupta K, Cohen ML, Bu C, Good SS, Moussa A, Rush R.

Eur J Drug Metab Pharmacokinet. 2016 Oct;41(5):567-74. doi: 10.1007/s13318-015-0267-4. Epub 2015 Apr 22.

PMID:
25898809
3.

Overcoming stability challenges in the quantification of tissue nucleotides: determination of 2'-C-methylguanosine triphosphate concentration in mouse liver.

Rashidzadeh H, Bhadresa S, Good SS, Larsson Cohen M, Gupta KS, Rush WR.

Biol Pharm Bull. 2015;38(3):380-8. doi: 10.1248/bpb.b14-00565.

4.

Estimation of human drug clearance using multiexponential techniques.

Goteti K, Brassil PJ, Good SS, Garner CE.

J Clin Pharmacol. 2008 Oct;48(10):1226-36. doi: 10.1177/0091270008320369. Epub 2008 Jun 16.

PMID:
18559487
5.

Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication.

Koszalka GW, Johnson NW, Good SS, Boyd L, Chamberlain SC, Townsend LB, Drach JC, Biron KK.

Antimicrob Agents Chemother. 2002 Aug;46(8):2373-80.

6.

Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action.

Biron KK, Harvey RJ, Chamberlain SC, Good SS, Smith AA 3rd, Davis MG, Talarico CL, Miller WH, Ferris R, Dornsife RE, Stanat SC, Drach JC, Townsend LB, Koszalka GW.

Antimicrob Agents Chemother. 2002 Aug;46(8):2365-72.

7.

Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89.

Faletto MB, Miller WH, Garvey EP, St Clair MH, Daluge SM, Good SS.

Antimicrob Agents Chemother. 1997 May;41(5):1099-107.

8.

1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity.

Daluge SM, Good SS, Faletto MB, Miller WH, St Clair MH, Boone LR, Tisdale M, Parry NR, Reardon JE, Dornsife RE, Averett DR, Krenitsky TA.

Antimicrob Agents Chemother. 1997 May;41(5):1082-93.

10.

In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase.

Huber BE, Austin EA, Good SS, Knick VC, Tibbels S, Richards CA.

Cancer Res. 1993 Oct 1;53(19):4619-26.

PMID:
8402637
11.

Synthesis and biological evaluation of dinucleoside methylphosphonates of 3'-azido-3'-deoxythymidine and 2', 3'-dideoxycytidine.

Puech F, Gosselin G, Balzarini J, Good SS, Rideout JL, De Clercq E, Imbach JL.

Antiviral Res. 1990 Jul;14(1):11-23.

PMID:
1964371
12.

Isolation and characterization of an ether glucuronide of zidovudine, a major metabolite in monkeys and humans.

Good SS, Koble CS, Crouch R, Johnson RL, Rideout JL, de Miranda P.

Drug Metab Dispos. 1990 May-Jun;18(3):321-6.

PMID:
1974193
13.

Tissue distribution and metabolic disposition of zidovudine in rats.

de Miranda P, Burnette TC, Good SS.

Drug Metab Dispos. 1990 May-Jun;18(3):315-20.

PMID:
1974192
14.

Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex.

de Miranda P, Good SS, Yarchoan R, Thomas RV, Blum MR, Myers CE, Broder S.

Clin Pharmacol Ther. 1989 Nov;46(5):494-500.

PMID:
2582706
15.

Simultaneous quantification of zidovudine and its glucuronide in serum by high-performance liquid chromatography.

Good SS, Reynolds DJ, de Miranda P.

J Chromatogr. 1988 Sep 23;431(1):123-33.

PMID:
3235523
16.

Pharmacokinetics and bioavailability of zidovudine in humans.

Blum MR, Liao SH, Good SS, de Miranda P.

Am J Med. 1988 Aug 29;85(2A):189-94.

PMID:
3165603
17.

Disposition in the dog and the rat of 2, 6-diamino-9-(2-hydroxyethoxymethyl)purine (A134U), a potential prodrug of acyclovir.

Good SS, Krasny HC, Elion GB, de Miranda P.

J Pharmacol Exp Ther. 1983 Dec;227(3):644-51.

PMID:
6655561
18.

A single-tube radioimmunoassay for the antiviral agent 2,6-diamino-9-(2-hydroxyethoxymethyl)purine (A134U).

Quinn RP, Good SS, Gerald L, Sabatka JJ.

Anal Biochem. 1983 Oct 1;134(1):16-25.

PMID:
6660486
19.

Metabolic disposition of acyclovir in the guinea pig, rabbit, and monkey.

Good SS, de Miranda P.

Am J Med. 1982 Jul 20;73(1A):91-5.

PMID:
7102713
20.

Metabolic fate of radioactive acyclovir in humans.

de Miranda P, Good SS, Krasny HC, Connor JD, Laskin OL, Lietman PS.

Am J Med. 1982 Jul 20;73(1A):215-20.

PMID:
7102704
21.

Disposition of intravenous radioactive acyclovir.

de Miranda P, Good SS, Laskin OL, Krasny HC, Connor JD, Lietman PS.

Clin Pharmacol Ther. 1981 Nov;30(5):662-72.

PMID:
7297024
22.

A sensitive radioimmunoassay for the antiviral agent BW248U [9-(2-hydroxyethoxymethyl)guanine].

Quinn RP, de Miranda P, Gerald L, Good SS.

Anal Biochem. 1979 Oct 1;98(2):319-28. No abstract available.

PMID:
573975
23.

Transport of threonine and tryptophan by rat brain slices: relation to other amino acids at concentrations found in plasma.

Tews JK, Good SS, Harper AE.

J Neurochem. 1978 Sep;31(3):581-9. No abstract available.

PMID:
681941

Supplemental Content

Support Center